At the 2025 Shenzhen International High-Performance Medical Device Exhibition, Shenzhen Kexing Medical Device Co., Ltd., a subsidiary of Kexing Biopharm, made a remarkable debut with its comprehensive portfolio in the medical aesthetics sector. The showcased products spanned various stages of development, highlighting the company's dual strategic focus on medical devices and cosmetics. The lineup included the "Recombinant Humanized Type III Collagen Lyophilized Fiber," a Class III medical device currently in clinical trials; a recombinant collagen dressing, a Class II medical device for which registration has been submitted; and the already commercially available Shangxi Biology® brand skincare products.
Headquartered in Nanshan, Shenzhen, Shenzhen Kexing Medical Device Co., Ltd. represents Kexing Biopharm' strategic foray into the medical device sector. As an international innovator, it is dedicated to merging cutting-edge biotechnology with scientific medical aesthetics and anti-aging solutions. Shenzhen provides fertile ground for the transformation and innovative development of high-end medical devices and biotechnology. True to this spirit, Shenzhen Kexing Medical Device is driven by an "innovation DNA." As an emerging innovator in the medical device field, the company is committed to building advanced technological platforms and developing internationally competitive, high-quality products to fuel the industry's high-quality growth.
Core Technology as the Cornerstone, Flagship Products Steal the Spotlight
The centerpiece of Shenzhen Kexing Medical Device's exhibition was its GB14 Project recombinant Type III collagen series, which drew significant attention due to its advanced biotechnological advantages. With an amino acid sequence highly homologous to the human body's natural Type III collagen, this series offers excellent biocompatibility and bioactivity. It avoids the potential immune rejection risks associated with traditional animal-derived collagen. Utilizing advanced Pichia pastoris fermentation technology, it provides safer and longer-lasting systematic solutions in the fields of anti-aging and repair.
Recombinant humanized Type III collagen boasts a wide range of applications, covering diverse scenarios such as aesthetic dermal fillers, post-procedure repair following energy-based device treatments, and daily precision skincare. The exhibited Class III medical device product, "Recombinant Humanized Type III Collagen Lyophilized Fiber," recently completed enrollment of its first subject in clinical trials. Its primary future application is for facial dermal tissue filling injections to correct dynamic forehead wrinkles, including glabellar lines, horizontal forehead lines, and crow's feet. Meanwhile, the Class II medical device product, the recombinant collagen dressing, has submitted its registration application. Upon approval, it will enter the market application stage, paving the way for the Class III product.
On the consumer end, Shenzhen Kexing Medical Device's skincare brand, Shangxi Biology®, has already launched successfully. Its cosmetic-grade products, such as recombinant Type III collagen masks and single-use essences , are not only best-sellers on e-commerce platforms but have also achieved a breakthrough by expanding into Southeast Asian markets. At this exhibition, Shangxi Biology® also unveiled several new products, including the Age-Defying Brightening Cream and Nourishing Time-Repair Mask, attracting considerable attention from visitors and showcasing the brand's increasingly diverse product portfolio.
Overseas Expansion Consortium Empowers Global Reach
The Shenzhen International High-Performance Medical Device and Innovative Medicine Exhibition actively fostered an efficient collaborative ecosystem connecting industry, academia, research, medicine, and capital. It hosted multiple forums addressing core industry needs. One key event, the "Shenzhen Service Supply-Demand Matching Activity Supporting Private Enterprises in Expanding International Markets (Pharmaceuticals & Medical Devices Edition)," brought together representatives from government, enterprises, legal, and financial sectors to share insights, tackle challenges, and assist companies in global market expansion. As a founding unit of the Shenzhen Pharmaceutical and Medical Device Industry Overseas Expansion Consortium, Kexing Biopharm was invited to participate in the forum's panel discussion.
Representing the company, Dr. Shao Ke, Vice President of Kexing Biopharm, shared strategies and case studies on international expansion from a practical business perspective. He systematically elaborated on the necessity for Chinese pharmaceutical companies to go global and outlined differentiated competitive strategies. Dr. Shao pointed out the vast potential of overseas markets, making the "going out" strategy imperative, particularly in high-growth areas like oncology, autoimmune diseases, and metabolic disorders. He also acknowledged challenges such as registration barriers and commercialization difficulties. Kexing Biopharm' overseas commercial platform has matured, with marketing channels now covering approximately 70 countries and regions, including the EU. The company has already partnered with several domestic firms to promote their high-quality products abroad. Moving forward, the Overseas Expansion Consortium will continue to provide comprehensive, one-stop global expansion services for pharmaceutical and medical device companies in Shenzhen and across China.
This appearance at the 2025 Shenzhen International High-Performance Medical Device Exhibition served as a vital platform for Shenzhen Kexing Medical Device to showcase its core technologies and product matrix. It also marks a new chapter in the company's journey into the anti-aging field with collagen-based solutions. Looking ahead, Shenzhen Kexing Medical Device will leverage this exhibition as a springboard to deepen its commitment to innovative R&D, accelerate the clinical translation and internationalization of its products, and contribute to bringing high-performance medical devices to the global stage
https://www.kexingbiopharm.com/
Kexing Biopharm
+ There are no comments
Add yours